Status:

COMPLETED

Survivor-Sleep Health Information Program

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborating Sponsors:

Children's Cancer Research Fund

Conditions:

Sleep Problem

Insomnia

Eligibility:

All Genders

5-12 years

Phase:

NA

Brief Summary

The purpose of the study is to learn if an educational program delivered to parents/guardians can help improve the sleep of children experiencing sleep problems after completing cancer treatment. The ...

Detailed Description

This study will evaluate Survivor-SHIP in a single-arm trial of 20 off-treatment childhood cancer survivors (ages 5-12). The intervention is an adapted version of the family-centered Sleep Health Prog...

Eligibility Criteria

Inclusion

  • Child aged 5-12 years, with a history of a cancer diagnosis (except non-melanoma skin cancer).
  • No cancer therapy (excluding chemoprevention) in the past 6 months, and no further therapy planned.
  • Child meets diagnostic criteria for insomnia disorder as determined by insomnia screening criteria (see Appendix A)
  • Parent/guardian is able to read and write in English.
  • Regular access to a computer/smartphone with internet access at home.

Exclusion

  • Reports child has been diagnosed with a Seizure Disorder or has experienced a seizure in the past 12 months.
  • Reports child has been diagnosed with a developmental disorder such as Autism Spectrum Disorder, Cerebral Palsy, Fragile X Syndrome, or Moderate to Profound Intellectual Disability.
  • Reports child has been diagnosed with sleep apnea, and are not receiving recommended medical treatment for their sleep apnea.
  • Intention to adjust (decrease or increase) child's use of any prescribed or over-the-counter sleep medications during the study period.
  • Any impairment (e.g., hearing, visual, cognitive) that interferes with the parent/guardian's ability to complete all study procedures independently.

Key Trial Info

Start Date :

May 24 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2022

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT04863157

Start Date

May 24 2021

End Date

December 31 2022

Last Update

January 18 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215